{
  "id": 17247522,
  "title": "AstraZeneca says reorg could mean R&D cuts and trials shifted to emerging markets",
  "url": "https://urgent.news/2026/10/30/astrazeneca-says-reorg-could-mean-r-d-cuts-and-trials-shifted-to",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-30T15:36:16.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/astrazeneca-says-reorg-could-mean-rd-cuts-and-trials-shifted-to-emerging-markets/"
  },
  "original_language": "en",
  "account": null,
  "summary": "AstraZeneca’s leadership hinted at where the cost cuts and job losses from the company’s new restructuring program might fall on a call with journalists Friday. “We are losing patent protection for Farxiga ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}